Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison-Reference-Cited by-同舟云学术

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison

Published:2024-08-22 Issue:9 Volume:40 Page:1597-1603
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Bar Noffar¹,Diels Joris²^ORCID,van Sanden Suzy²,Mendes João³,Hernando Teresa⁴,Burnett Heather⁵,Cost Patricia⁶,Schecter Jordan M.⁷,Lendvai Nikoletta⁷,Patel Nitin⁸,Ishida Tadao⁹,Er Jeremy¹⁰¹¹,Harrison Simon J.¹⁰¹²,Lopez-Muñoz Nieves¹³

Affiliation:

1. Section of Hematology, Department of Internal Medicine, Yale School of Medicine University, New Haven, CT, USA

2. Janssen Pharmaceutica NV, Beerse, Belgium

3. Jan-Cilag Farmacêutica, Porto Salvo, Portugal

4. Janssen-Cilag S.A, Madrid, Spain

5. Evidera, a part of Thermo Fisher Scientific, St-Laurent, Canada

6. Janssen Global Services, LLC, Raritan, NJ, USA

7. Janssen Research and Development LLC, Raritan, NJ, USA

8. Legend Biotech USA Inc, Somerset, NJ, USA

9. Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

10. Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville, VIC, Australia

11. Department of Medical Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia

12. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia

13. Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2391112

Reference23 articles.

1. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

2. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis

3. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

4. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

5. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy